Prelude Therapeutics Inc Financials
This page shows Prelude Therapeutics Inc (PRLD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Prelude Therapeutics Inc has an operating margin of -861.3%, meaning the company retains $-861 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -1995.9% the prior year.
Prelude Therapeutics Inc's revenue surged 73.4% year-over-year to $12.1M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Prelude Therapeutics Inc carries a low D/E ratio of 1.06, meaning only $1.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 80/100, indicating a strong balance sheet with room for future borrowing.
Prelude Therapeutics Inc's current ratio of 1.99 indicates adequate short-term liquidity, earning a score of 36/100. The company can meet its near-term obligations, though with limited headroom.
While Prelude Therapeutics Inc generated -$56.3M in operating cash flow, capex of $67K consumed most of it, leaving -$56.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Prelude Therapeutics Inc generates a -145.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -96.7% the prior year.
Prelude Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Prelude Therapeutics Inc generates $0.57 in operating cash flow (-$56.3M OCF vs -$99.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Prelude Therapeutics Inc generated $12.1M in revenue in fiscal year 2025. This represents an increase of 73.4% from the prior year.
Prelude Therapeutics Inc's EBITDA was -$102.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.4% from the prior year.
Prelude Therapeutics Inc reported -$99.5M in net income in fiscal year 2025. This represents an increase of 21.8% from the prior year.
Prelude Therapeutics Inc earned $-1.29 per diluted share (EPS) in fiscal year 2025. This represents an increase of 23.2% from the prior year.
Cash & Balance Sheet
Prelude Therapeutics Inc generated -$56.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.6% from the prior year.
Prelude Therapeutics Inc held $35.3M in cash against $0 in long-term debt as of fiscal year 2025.
Margins & Returns
Prelude Therapeutics Inc's operating margin was -861.3% in fiscal year 2025, reflecting core business profitability. This is up 1134.6 percentage points from the prior year.
Prelude Therapeutics Inc's net profit margin was -819.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 997.2 percentage points from the prior year.
Prelude Therapeutics Inc's ROE was -145.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 48.2 percentage points from the prior year.
Capital Allocation
Prelude Therapeutics Inc invested $94.3M in research and development in fiscal year 2025. This represents a decrease of 20.1% from the prior year.
Prelude Therapeutics Inc invested $67K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 91.2% from the prior year.
PRLD Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $6.5M | N/A | N/A | N/A | $3.0M | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $21.7M-15.8% | $25.8M-10.5% | $28.8M | N/A | $29.5M-0.2% | $29.5M+7.7% | $27.4M |
| SG&A Expenses | N/A | $5.2M-18.7% | $6.4M+10.7% | $5.8M | N/A | $7.9M+3.4% | $7.7M+10.4% | $6.9M |
| Operating Income | N/A | -$20.4M+36.6% | -$32.2M+7.0% | -$34.6M | N/A | -$34.4M+7.5% | -$37.2M-8.2% | -$34.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$19.7M+36.8% | -$31.2M+2.7% | -$32.1M | N/A | -$32.3M+7.1% | -$34.7M-10.5% | -$31.4M |
| EPS (Diluted) | N/A | $-0.26+36.6% | $-0.41+2.4% | $-0.42 | N/A | $-0.43+6.5% | $-0.46-9.5% | $-0.42 |
PRLD Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $141.3M+49.1% | $94.8M-17.5% | $114.9M-18.6% | $141.3M-19.5% | $175.5M-11.0% | $197.2M-12.1% | $224.3M-9.2% | $247.1M |
| Current Assets | $105.7M+81.2% | $58.3M-24.1% | $76.9M-24.9% | $102.4M-24.6% | $135.9M-13.1% | $156.4M-14.4% | $182.7M-11.0% | $205.4M |
| Cash & Equivalents | $35.3M-25.8% | $47.5M+84.6% | $25.8M-36.1% | $40.3M+222.8% | $12.5M+12.0% | $11.1M-60.0% | $27.8M+12.6% | $24.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $72.7M+100.7% | $36.2M-7.3% | $39.1M+2.6% | $38.1M-13.6% | $44.1M+8.0% | $40.8M-2.9% | $42.0M+15.5% | $36.4M |
| Current Liabilities | $53.0M+191.3% | $18.2M-13.0% | $20.9M+5.7% | $19.8M-22.8% | $25.6M+15.4% | $22.2M-4.8% | $23.3M+32.3% | $17.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $68.6M+17.3% | $58.5M-22.8% | $75.8M-26.5% | $103.2M-21.5% | $131.5M-16.0% | $156.4M-14.2% | $182.3M-13.5% | $210.7M |
| Retained Earnings | -$683.1M-2.5% | -$666.6M-3.0% | -$646.9M-5.1% | -$615.6M-5.5% | -$583.6M-5.2% | -$554.8M-6.2% | -$522.6M-7.1% | -$487.8M |
PRLD Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $23.1M+220.9% | -$19.1M+26.7% | -$26.1M+23.8% | -$34.2M-65.0% | -$20.7M+24.0% | -$27.3M-18.4% | -$23.1M+27.5% | -$31.8M |
| Capital Expenditures | $0 | $0-100.0% | $20K-57.4% | $47K-11.3% | $53K-15.9% | $63K-82.5% | $359K+24.2% | $289K |
| Free Cash Flow | $23.1M+220.9% | -$19.1M+26.7% | -$26.1M+23.9% | -$34.3M-64.8% | -$20.8M+24.0% | -$27.4M-16.8% | -$23.4M+27.0% | -$32.1M |
| Investing Cash Flow | -$60.3M-250.5% | $40.1M+248.0% | $11.5M-81.5% | $62.2M+181.2% | $22.1M+106.1% | $10.7M-58.9% | $26.1M-16.3% | $31.2M |
| Financing Cash Flow | $24.9M+498980.0% | -$5K-113.5% | $37K+123.1% | -$160K-370.6% | -$34K+74.0% | -$131K-322.0% | $59K+521.4% | -$14K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PRLD Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | -314.1% | N/A | N/A | N/A | -1145.9% | N/A | N/A |
| Net Margin | N/A | -303.5% | N/A | N/A | N/A | -1075.7% | N/A | N/A |
| Return on Equity | N/A | -33.7%+7.5pp | -41.2%-10.1pp | -31.1% | N/A | -20.6%-1.6pp | -19.1%-4.1pp | -14.9% |
| Return on Assets | N/A | -20.8%+6.4pp | -27.2%-4.5pp | -22.7% | N/A | -16.4%-0.9pp | -15.5%-2.8pp | -12.7% |
| Current Ratio | 1.99-1.2 | 3.21-0.5 | 3.68-1.5 | 5.18-0.1 | 5.30-1.7 | 7.04-0.8 | 7.83-3.8 | 11.64 |
| Debt-to-Equity | 1.06+0.4 | 0.62+0.1 | 0.52+0.1 | 0.37+0.0 | 0.34+0.1 | 0.26+0.0 | 0.23+0.1 | 0.17 |
| FCF Margin | N/A | -294.1% | N/A | N/A | N/A | -912.0% | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Prelude Therapeutics Inc's annual revenue?
Prelude Therapeutics Inc (PRLD) reported $12.1M in total revenue for fiscal year 2025. This represents a 73.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Prelude Therapeutics Inc's revenue growing?
Prelude Therapeutics Inc (PRLD) revenue grew by 73.4% year-over-year, from $7.0M to $12.1M in fiscal year 2025.
Is Prelude Therapeutics Inc profitable?
No, Prelude Therapeutics Inc (PRLD) reported a net income of -$99.5M in fiscal year 2025, with a net profit margin of -819.6%.
What is Prelude Therapeutics Inc's EBITDA?
Prelude Therapeutics Inc (PRLD) had EBITDA of -$102.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Prelude Therapeutics Inc's operating margin?
Prelude Therapeutics Inc (PRLD) had an operating margin of -861.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Prelude Therapeutics Inc's net profit margin?
Prelude Therapeutics Inc (PRLD) had a net profit margin of -819.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Prelude Therapeutics Inc's return on equity (ROE)?
Prelude Therapeutics Inc (PRLD) has a return on equity of -145.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Prelude Therapeutics Inc's free cash flow?
Prelude Therapeutics Inc (PRLD) generated -$56.4M in free cash flow during fiscal year 2025. This represents a 45.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Prelude Therapeutics Inc's operating cash flow?
Prelude Therapeutics Inc (PRLD) generated -$56.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Prelude Therapeutics Inc's total assets?
Prelude Therapeutics Inc (PRLD) had $141.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Prelude Therapeutics Inc's capital expenditures?
Prelude Therapeutics Inc (PRLD) invested $67K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Prelude Therapeutics Inc spend on research and development?
Prelude Therapeutics Inc (PRLD) invested $94.3M in research and development during fiscal year 2025.
What is Prelude Therapeutics Inc's current ratio?
Prelude Therapeutics Inc (PRLD) had a current ratio of 1.99 as of fiscal year 2025, which is generally considered healthy.
What is Prelude Therapeutics Inc's debt-to-equity ratio?
Prelude Therapeutics Inc (PRLD) had a debt-to-equity ratio of 1.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Prelude Therapeutics Inc's return on assets (ROA)?
Prelude Therapeutics Inc (PRLD) had a return on assets of -70.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Prelude Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Prelude Therapeutics Inc (PRLD) had $35.3M in cash against an annual operating cash burn of $56.3M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Prelude Therapeutics Inc's Piotroski F-Score?
Prelude Therapeutics Inc (PRLD) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Prelude Therapeutics Inc's earnings high quality?
Prelude Therapeutics Inc (PRLD) has an earnings quality ratio of 0.57x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Prelude Therapeutics Inc?
Prelude Therapeutics Inc (PRLD) scores 36 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.